Immatics Q3 2026 net loss widens 50% to EUR 76.02 million

• Immatics’ third-quarter 2026 net loss widened 50% year-over-year to EUR 76.02 million; revenue rose 33% to EUR 6.92 million.
• Research and development expenses jumped 49% year-over-year to EUR 70.27 million, primarily due to clinical-trial costs, particularly SUPRAME.
• Cash, cash equivalents and other financial assets totaled EUR 472.3 million at September 30, 2026, with cash reach projected into Q4 2028.
• SUPRAME topline data remain expected in the first half of 2027, followed by a BLA submission for anzu-cel in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immatics NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611100700OMX_____CNEWS_EN_GNW1001302813_en) on November 10, 2026, and is solely responsible for the information contained therein.